Reply: Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
| Autor: | Bradley CL; Department of Clinical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC, USA., McMillin SM; Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC, USA., Hwang AY; Department of Pharmacy Practice, School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA., Sherrill CH; Division of Practice Advancement and Clinical Education, UNC Eshelman School of Pharmacy, Asheville, NC, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Annals of pharmacotherapy [Ann Pharmacother] 2024 Apr; Vol. 58 (4), pp. 446-447. Date of Electronic Publication: 2024 Jan 21. |
| DOI: | 10.1177/10600280231224021 |
| Abstrakt: | Competing Interests: Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|